Krakowska Akademia Neurologii Sp. z o.o.

The Centrum Neurologii Klinicznej at Krakowska Akademia Neurologii focuses on immune system diseases that affect the nervous system, especially multiple sclerosis and myasthenia gravis. Researchers are evaluating new biologic agents and complement inhibitors to improve long‑term outcomes for patients.

• Evaluation of anti‑B‑cell therapy in relapsing multiple sclerosis
• Assessment of complement inhibition for generalized myasthenia gravis
• Investigation of FcRn antagonists in AChR‑positive myasthenia gravis
• Long‑term safety of subcutaneous infusion therapy in advanced Parkinson’s disease

With 33 active trials and 15 investigators, the site advances therapeutic options for autoimmune neurological conditions while maintaining a strong safety monitoring program.

Studies at the center target early and progressive forms of movement disorders, aiming to slow disease progression and enhance motor function in Parkinson’s disease, Huntington’s disease and related conditions.

• Continuous subcutaneous infusion of a dopamine agonist for advanced Parkinson’s disease
• Antibody therapy directed at α‑synuclein in early Parkinson’s disease
• Disease‑modifying antisense treatment for early Huntington’s disease
• CSF huntingtin protein monitoring in prodromal Huntington’s disease

The program emphasizes long‑term safety and efficacy, offering participants access to innovative treatments that may alter disease trajectories.

Research efforts address the early stages of Alzheimer’s disease and related cognitive impairments, testing interventions that could preserve memory and reduce neuropsychiatric symptoms.

• Oral semaglutide impact on cognition in Mild Cognitive Impairment
• Intrathecal antisense therapy for early symptomatic Alzheimer’s disease
• Agitation reduction strategies in Alzheimer’s disease dementia
• Clinical rating scale improvements with novel agents in early Alzheimer’s disease

Krakowska Akademia Neurologii supports patients through comprehensive monitoring and provides opportunities to join trials focused on slowing cognitive decline.

The site conducts trials to improve seizure control and migraine prevention, evaluating newer formulations and delivery methods for better patient outcomes.

• Extended‑release levetiracetam for drug‑resistant focal onset seizures
• Botulinum toxin injection for upper‑limb spasticity after stroke
• Xeomin® therapy for reducing monthly attacks in chronic migraine
• Xeomin® therapy for reducing monthly attacks in episodic migraine

These studies aim to enhance quality of life by delivering faster, more durable relief for patients living with seizure disorders and migraine.